Biotime News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

02.10.13	MorphoSys To Receive Clinical Milestone Payment From Novartis - Quick Facts (RTTNews)
16.12.11	BioTime’s Subsidiary OncoCyte Corporation Announces Plans for the Novel Pan-Cancer Diagnostic Product PanC-DxTM (Businesswire)
12.12.11	BioTime Successfully Completes HyStem®-Rx Preclinical ISO 10993 Studies (Businesswire)
29.11.11	BioTime, Inc. Appoints Andrew C. von Eschenbach, M.D. to its Board of Directors (Businesswire)
14.11.11	BioTime Cell Information Now Available in GeneCards® (Businesswire)
08.11.11	BioTime Announces Third Quarter 2011 Financial Results and Recent Corporate Accomplishments (Businesswire)
10.10.11	BioTime CEO Michael D. West to Present at GTC 2011 5th Advances in Stem Cell Discovery & Development Conference (Businesswire)
12.09.11	BioTime CEO Michael D. West to Present at Stem Cells USA & Regenerative Medicine Congress 2011 (Businesswire)
09.06.11	BioTime Reports First Complete Sequencing of the Nuclear Genome of Five GMP-Compliant Human Embryonic Stem Cell Lines at Jefferies 2011 Global Healthcare Conference (Businesswire)
09.06.11	BioTime Reports First Complete Sequencing of the Nuclear Genome of Five GMP-Compliant Human Embryonic Stem Cell Lines at Jefferies 2011 Global Healthcare Conference (Businesswire)
02.06.11	BioTime CEO Dr. Michael West to Present at the Jefferies 2011 Global Healthcare Conference (Businesswire)
14.02.11	BioTime Announces Agreement To Acquire Glycosan BioSystems (Businesswire)
14.02.11	Evergreen Solar Announces Expiration and Results of Exchange Offers and Consent Solicitation (Businesswire)
28.01.11	BioTime Acquires Assets of Cell Targeting, Inc. (Businesswire)
10.01.11	BioTime’s CEO Michael West to Present Preclinical Data on OTX-CP03 and OTX-CP07 for the Treatment of Osteoarthritis at STEM 2011 in Gurgaon, India (Businesswire)
10.11.10	BioTime’s CEO Michael West to Present Keynote Address at BIT Life Sciences’ 3rd Annual World Congress of Regenerative Medicine & Stem Cells 2010 in Shanghai, China (Businesswire)
14.10.10	BioTime’s CEO Michael West to Speak at GTCbio and Unveil 12 New Diverse Cell Lines to be Launched November 1, 2010 (Businesswire)
11.10.10	Cell Cure Neurosciences’ Shareholders Will Invest $7.1 M in the Company’s Development of Innovative Stem Cell Treatments for Neural and Retinal Diseases (Businesswire)
09.09.10	BioTime Announces Executive Management Changes (Businesswire)
21.05.10	Dex One Corporation Chairman & CEO Announces Retirement; Board To Initiate Executive Search (Businesswire)
29.04.10	BioTime, Inc. Announces Agreement to Acquire ES Cell International (Businesswire)
16.03.10	BioTime, Inc. Reports Peer-Reviewed Scientific Publication on the Reversal of the Developmental Aging of Normal Human Cells (Businesswire)
07.01.10	BioTime Subsidiary OncoCyte Corporation Receives Second $2,000,000 Equity Tranche; BioTime Plans Additional $2,250,000 Investment (Businesswire)
04.12.09	BioTime CEO Dr. Michael West to Ring The Opening Bell at the New York Stock Exchange (Businesswire)
23.09.09	BioTime, Inc. to Form Asian Subsidiary (Businesswire)
23.09.09	BioTime, Inc. to Form Asian Subsidiary (Businesswire)
10.08.09	BioTime Appoints Walter Funk Vice President for Stem Cell Research (Businesswire)
30.03.09	BioTime Announces 2008 Year-End Results (Businesswire)
21.01.09	BioTime Launches New Stem Cell Lines in Anticipation of President Obama’s Removal of Restrictions on Federal Funding of Embryonic Stem Cell Research (Businesswire)
21.11.08	BioTime Inc. Announces Third Quarter 2008 Financial Results (Businesswire)
16.07.08	Embryome Sciences, Inc. Acquires Exclusive License for ACTCellerate Technology (Businesswire)
15.05.08	BioTime CEO Dr. Michael West Presents at European Stem Cells & Regenerative Medicine Congress 2008 (Businesswire)
02.11.07	BioTime Announces Joint Hypothermic Medicine Study With Argonne National Laboratory (Businesswire)
11.10.07	BioTime Names Dr. Michael D. West as CEO and Announces Entry Into Stem Cell Research and Regenerative Medicine (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Logitech Intl	81.34	1.80 %	K V
Kuehne+Nagel Int	206.90	1.12 %	K V
Lonza Grp	583.00	0.45 %	K V
Swiss Life Hldg	734.40	0.36 %	K V
Geberit	502.20	0.28 %	K V
Novartis	89.54	-0.21 %	K V
Alcon	80.64	-0.32 %	K V
Nestle	73.88	-0.40 %	K V
ABB	53.24	-0.60 %	K V
Sonova Hldg	313.60	-1.54 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Biotime IncShs

Aktien Top/Flop

Meistgelesene Nachrichten